US FDA Experts Advise Industry On How To Rid Drug Manufacturing Processes Of Nitrosamines
No Uniform Checklist for Performing Risk Assessments
Executive Summary
FDA officials say that process and supply chain risks are some of the root causes driving many of the nitrosamine contamination problems in recent months and manufacturers should work to contain and control these risks.
You may also be interested in...
US FDA Gives Industry An Extension On Nitrosamine Risk Assessments
Drug makers win one-month reprieve for their nitrosamine risk assessments for new drug products and approved products.
Perrigo Among Firms Requesting Delay In Conducting US Nitrosamine Risk Assessments
Perrigo, Pfizer want FDA to postpone its March deadline for conducting nitrosamine risk assessments. Generics executive cites “serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Manufacturers Want Delay In Conducting US Nitrosamine Risk Assessments
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.